博文
抗肺动脉高压药物介导的前列环素受体激活以及配体选择性机制
||
抗肺动脉高压药物介导的前列环素受体激活以及配体选择性机制https://www.ebiotrade.com/newsf/2024-2/20240215063844509.htm
http://www.pubmedplus.cn/P/SearchQuickResult?wd=98dd34f1-b9d3-404d-9bcd-6a9de18a5d6a
| 01. | Humans | 110 篇 | 58.201% |
| 02. | Epoprostenol | 52 篇 | 27.513% |
| 03. | Hypertension, Pulmonary | 48 篇 | 25.397% |
| 04. | Pulmonary Arterial Hypertension | 36 篇 | 19.048% |
| 05. | Animals | 23 篇 | 12.169% |
| 06. | Antihypertensive Agents | 22 篇 | 11.640% |
| 07. | Familial Primary Pulmonary Hypertension | 22 篇 | 11.640% |
| 08. | Prostaglandins I | 20 篇 | 10.582% |
| 09. | Female | 19 篇 | 10.053% |
| 10. | Retrospective Studies | 16 篇 | 8.466% |
(3)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
https://m.sciencenet.cn/blog-280034-1421794.html
上一篇：钾通道Kir4.1是具潜力的快速抗抑郁药物靶点
下一篇：糖尿病患者胰腺胰岛β细胞线粒体稳态失衡新分子机制并提出T2D原始创新药物靶标
